Single-cell RNA sequencing reveals enhanced antitumor immunity after combined application of PD-1 inhibitor and Shenmai injection in non-small cell lung cancer

BACKGROUND: Immune checkpoint inhibitors (ICIs) have altered the clinical management of non-small cell lung cancer (NSCLC). However, the low response rate, severe immune-related adverse events (irAEs), and hyperprogressive disease following ICIs monotherapy require attention. Combination therapy may...

Descripción completa

Detalles Bibliográficos
Autores principales: Yu, Dingyi, Yang, Penghui, Lu, Xiaoyan, Huang, Shaoze, Liu, Li, Fan, Xiaohui
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10332015/
https://www.ncbi.nlm.nih.gov/pubmed/37430270
http://dx.doi.org/10.1186/s12964-023-01184-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10332015/
https://www.ncbi.nlm.nih.gov/pubmed/37430270
http://dx.doi.org/10.1186/s12964-023-01184-3

Ejemplares similares